KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	8.74B -33.6%
Revenue (ttm)	6.58B -21.7%
Net Income	349.94M -46.0%
EPS	0.46 -46.5%
Shares Out	756.98M
PE Ratio	25.09
Forward PE	25.64
Dividend	0.18 (1.58%)
Ex-Dividend Date	Jul 30, 2025

Volume	4,474,260
Average Volume	6,375,742
Open	11.50
Previous Close	11.54
Day's Range	11.33 - 11.57
52-Week Range	11.08 - 18.64
Beta	0.11
RSI	43.62
Earnings Date	Mar 20, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections and others. The company’s brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco. It markets art...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,275
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.74% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.